低暴力骨折但无骨质疏松症
本文讨论临床中用双能X线吸收法(DXA)测定的面积骨密度(aBMD)评估骨折风险时,多数低暴力骨折患者T值不低于-2.5、未达WHO骨质疏松诊断标准,部分骨密度甚至未降低。某些疾病或药物易在骨密度未明显降低时导致骨折。作者推荐对部分发生主要脆性骨折(尤其椎体或髋部)的患者,即使aBMD T值高于-2.5也应治疗。
要点
- 多数低暴力骨折患者DXA T值不低于-2.5,不符合WHO骨质疏松诊断。
- 脊柱关节病、慢性肾脏病及矿物质骨异常、糖尿病、肥胖,或糖皮质激素、芳香化酶抑制剂易在骨密度未明显降低时致骨折。
- 作者推荐对部分主要脆性骨折(尤其椎体或髋部)患者,即使aBMD T值高于-2.5也给予治疗。
核心结论
- 作者推荐对部分发生主要脆性骨折(尤其椎体或髋部)的患者,即使面积骨密度T值高于-2.5也应治疗。
研究设计与样本
- 本文为综述,围绕低暴力骨折但未达DXA骨质疏松诊断者的骨密度评估与治疗证据进行讨论。
主要发现
- 基于流行病学考虑,WHO将DXA T值<-2.5定义为骨质疏松,但多数低暴力骨折患者T值不低于-2.5,部分患者骨密度完全未降低。
- 脊柱关节病、慢性肾脏病及矿物质骨异常、糖尿病、肥胖,或糖皮质激素、芳香化酶抑制剂更易在骨密度未明显降低时导致骨折。
- 在骨密度偏低或正常的脆性骨折患者中,几乎全部药物治疗的疗效均在低骨密度患者中得到证实;但T值>-2患者的事后分析已有部分数据。
- 总体而言,对有既往脆性骨折(尤其椎体或髋部)的患者,治疗似乎有效。
关键数值与推荐
- WHO基于DXA的骨质疏松诊断标准为T值<-2.5。
- 作者推荐对部分主要脆性骨折(尤其椎体或髋部)患者,即使aBMD T值高于-2.5也应治疗。
临床怎么用
- 临床中用DXA测定的aBMD评估骨状态时,应认识到多数低暴力骨折患者T值不低于-2.5。
- 对脊柱关节病、慢性肾脏病及矿物质骨异常、糖尿病、肥胖,或使用糖皮质激素、芳香化酶抑制剂者,需注意其可能在骨密度未明显降低时发生骨折。
- 作者推荐对部分主要脆性骨折(尤其椎体或髋部)患者,即使aBMD T值高于-2.5也应治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In clinical practice, areal bone mineral density (aBMD) is usually measured using dual-energy X-ray absorptiometry (DXA) to assess bone status in patients with or without osteoporotic fracture. As BMD has a Gaussian distribution, it is difficult to define a cutoff for osteoporosis diagnosis. Based on epidemiological considerations, WHO defined a DXA-based osteoporosis diagnosis with a T-score <-2.5. However, the majority of individuals who have low-trauma fractures do not have osteoporosis with DXA (i.e., T-score <-2.5), and some of them have no decreased BMD at all. Some medical conditions (spondyloarthropathies, chronic kidney disease and mineral bone disorder, diabetes, obesity) or drugs (glucocorticoids, aromatase inhibitors) are more prone to cause fractures with subnormal BMD. In the situation of fragility fractures with subnormal or normal BMD, clinicians face a difficulty as almost all the pharmacologic treatments have proved their efficacy in patients with low BMD. However, some data are available in post hoc analyses in patients with T score >-2. Overall, in patients with a previous fragility fracture (especially vertebra or hip), treatments appear to be effective. Thus, the authors recommend treating some patients with a major fragility fracture even if areal BMD T score is above -2.5.
引用
- Lespessailles E, Cortet B, Legrand E, et al. Low-trauma fractures without osteoporosis. Osteoporos Int. 2017. PMID: 28161747. doi:10.1007/s00198-017-3921-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。